BDBM770213 4-(4-((1S,7R,8S)-8-chloro-2- azabicyclo[5.1.0]octan-2-yl)-8-fluoro-2- (((2R,7aS)-2-fluorotetrahydro-1H- pyrrolizin-7a(5H)-yl)methoxy- d2)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl- 6-fluoronaphthalen-2-amine::US20250282799, Example 342
SMILES [2H]C([2H])(Oc1nc(N2CCCC[C@H]3[C@H](Cl)[C@H]32)c2cnc(-c3cc(N)cc4ccc(F)c(C#C)c34)c(F)c2n1)[C@@]12CCCN1C[C@H](F)C2
InChI Key
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 2 hits for monomerid = 770213
TargetGTPase KRas [G12D]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Alterome Therapeutics
US Patent
Alterome Therapeutics
US Patent
Affinity DataIC50: 9.04nMAssay Description:The KRAS: CRAF PPI assay can be utilized to identify KRAS ‘ON’ state inhibitors, as the KRAS protein is loaded with GMPPNP (a non-hydrolyzable GTP an...More data for this Ligand-Target Pair
TargetGTPase KRas [G12V]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Alterome Therapeutics
US Patent
Alterome Therapeutics
US Patent
Affinity DataIC50: 54.7nMAssay Description:The KRAS: CRAF PPI assay can be utilized to identify KRAS ‘ON’ state inhibitors, as the KRAS protein is loaded with GMPPNP (a non-hydrolyzable GTP an...More data for this Ligand-Target Pair
